Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. - Wikidata - wikimedia - TriplyDB

Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.

Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.

http://www.wikidata.org/entity/Q46627140

about

Application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part I. Diagnosis of breast cancer prior to treatment The Role of F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast Cancer.Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer.Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer Defining the role of PET-CT in staging early breast cancer.Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.Clinical impact of (18)F-FDG PET/CT on initial staging and therapy planning for breast cancer.Bone scan or (18)f-fluorodeoxyglucose positron emission tomography/computed tomography; which modality better shows bone metastases of breast cancer?Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy (18)F-FDG/PET May Help to Identify a Subgroup of Patients with T1-T2 Breast Cancer and 1-3 Positive Lymph Nodes Who Are at a High Risk of Recurrence after Mastectomy Quantitative Evaluation of Therapeutic Response by FDG-PET-CT in Metastatic Breast Cancer Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging.Special Relevance of FDG-PET as an Upfront Diagnostic Modality at Initial Diagnosis and in Suspected Recurrence in Patients of Breast Carcinoma Hailing From Lower Socioeconomic Status Owing to Relative Late Presentation: A Pilot Study in a Medical C Clinical application of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in breast cancer.The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT.Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.Present and future role of FDG-PET/CT imaging in the management of breast cancer.Robot-assisted internal mammary lymph chain excision for breast cancer: A case report FDG-PET-CT for staging of high-risk breast cancer patients reduces the number of further examinations: A pilot study.Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT.18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.Should FDG PET/CT be used for the initial staging of breast cancer?Whole-body 18FDG-PET/CT or whole-body gadolinium-enhanced MRI for distant staging?Use of imaging for staging of early-stage breast cancer in two integrated health care systems: adherence with a choosing wisely recommendation.Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging.Detection of distant metastases in patients with locally advanced breast cancer: role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging with computed tomography scans.Comparisons of Positron Emission Tomography/Computed Tomography and Ultrasound Imaging for Detection of Internal Mammary Lymph Node Metastases in Patients With Breast Cancer and Pathologic Correlation by Ultrasound-Guided Biopsy Procedures.(18) F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities?Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.Preoperative PET/CT in early-stage breast cancer.Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact

P2860

Q26751999-D92F84F6-2931-4B9B-90C6-8F541388C43F Q34097237-CB71829B-E6C7-4FD6-BD78-2B88874C4C00 Q35552138-7C7D10A4-7D1F-4790-BB72-A87450CCB5CE Q35584721-C4AEE94B-4764-44AF-8F62-EFF83C1EEEDA Q35584948-B14E8DC4-880B-4831-AD4A-5D6D5A2EE118 Q35989958-E82A1FE4-3AC4-4461-AB09-9153129F8DFE Q36109265-131482E3-2444-43F8-9615-1E159A6726A2 Q36409205-BAF9B79B-6DD5-4559-B5F4-9EA6FE0DC7A4 Q36457878-7F28DB3E-4E98-4267-A054-42BE0C75FEE4 Q36476568-96352364-0397-4F69-9ABC-FAA39C224D25 Q36734702-2A4BB63A-5B1E-4184-878B-1C86CDC0B197 Q36832255-71D1E5FC-AFE0-4072-8A6A-5CE15D4B7A00 Q36883389-F2F383E5-916D-44D3-8674-9BB7A75B8786 Q37477631-EF0E956E-C6B8-4A42-94DA-23FED6B7141A Q37660339-ACD02045-6517-44C4-B22B-E74BF9A2A76F Q38165388-A31CE6B7-078D-4D5C-8335-FA41E43B7E1E Q38411448-3ABE7815-B400-4127-BF4C-31211C21F43C Q38445089-5BC42DB9-227C-4F8D-B343-702FD25EED0D Q38687620-F9E73581-7937-459C-A4F2-6FDD45447715 Q41622013-913D2E67-AC16-4E17-8ABC-0AEDBD09496D Q43217467-E02C10B6-E1FD-4B90-A4BE-11A013581DB6 Q44459789-9F046249-37A8-449B-A3E2-9FAC703F1FD5 Q45915234-0F080DFD-4143-4438-9D2D-A213E256C29A Q46008082-B3309EF4-CF97-4248-9B47-8C8E267414EB Q46014390-6AFC6A09-49B0-4562-AEC4-7A08C5816E54 Q46114763-8D6D9443-3072-4F3B-A89D-56F04101311F Q48118323-1075A820-B959-4382-AA48-57C77D00C9AA Q50145287-A0D14F69-0D6B-449F-B4F8-7BFFFCDD533A Q50877812-A2E06CBA-32EC-4E0B-B1CD-0AE4E2B1ABF3 Q50959115-A0942A49-B9C4-4491-9E5C-263E4D7B2A19 Q51408712-BF4ECF66-85F6-457F-B4FC-79A5EFAC8012 Q53076367-C228A897-366D-4F4E-B56A-6F558D3FA81D Q53089607-2C9265A5-ACAD-422D-ADCB-914C2A4785F5 Q53165455-19B3F3B7-AA50-4360-8DBB-7C6D43F16E95 Q53174047-86FA5889-94FF-47F2-9599-18F39CBF44A3 Q54336130-C2A2AA76-712C-4543-A3DD-0112CCF97A79 Q57728676-FF30F77D-1349-4A16-8D2A-6E9A1C1133D6

P2860

Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.

http://www.wikidata.org/entity/Q46627140

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Effect of (18)F-FDG PET/CT ima ...... tage II and III breast cancer.

@en

type

label

Effect of (18)F-FDG PET/CT ima ...... tage II and III breast cancer.

@en

prefLabel

Effect of (18)F-FDG PET/CT ima ...... tage II and III breast cancer.

@en

P1433

Q46627140-88368AE0-7C4C-42A1-ABD7-56B199C24920

P1476

Q46627140-C609CFE8-E2EA-4DAF-82D0-DFA7D3AEBBE2

P2093

Q46627140-2FCAFBD9-CB54-453F-ABAC-B94B53FA43AB

Q46627140-3F00C2FC-8A40-4C28-8B6E-4829D38845CC

Q46627140-4C44297D-F22C-483C-A253-EC31F7E47130

Q46627140-8214043C-1961-47B0-AE19-FD575516B12A

Q46627140-8B5213CB-465F-41E6-A2BC-98C68FAE1B11

Q46627140-91FAB379-8B51-4F70-9148-A95652429D14

Q46627140-A43FA350-67CA-4901-9311-44D557B3D1DA

Q46627140-AFB23563-AA31-4D22-AFBF-5857D8C2280D

Q46627140-B11DDA35-EB01-44A7-A06F-56EE676315D5

Q46627140-B38B6DE7-8EAD-48B0-B96F-B4A87E364246

P304

Q46627140-8EB63FBF-CF53-4FCC-9E9B-0092E7A1D43C

P31

Q46627140-72AD6ECB-29DC-42BA-B920-F9E268AD3CBC

P356

Q46627140-6941D8EA-E53F-4788-9336-820B68CCFF41

P407

Q46627140-A1E404A0-FEF0-4752-877C-F203127B1CBF

P433

Q46627140-0882780F-0594-4AA3-88AE-5B67147B1572

P478

Q46627140-F656BA62-3F99-44EA-83FA-71EF1BE549E1

P50

Q46627140-41E8AB76-A4B4-43E9-9BCF-FE9669A19E25

Q46627140-E7463364-6A5D-4DFC-AD48-2412F6B720AA

P577

Q46627140-BD8579FB-7EB1-46A7-81A6-DDDC06B84B1B

P698

Q46627140-E3536A05-CE82-4103-BF2F-10568D04390C

P356

J.IJROBP.2008.02.056

P1433

International Journal of Radiation Oncology Biology Physics

P1476

Effect of (18)F-FDG PET/CT ima ...... tage II and III breast cancer.

@en

P2093

Caroline Cuvier

http://www.w3.org/2001/XMLSchema#string

Christophe Hennequin

http://www.w3.org/2001/XMLSchema#string

David Groheux

http://www.w3.org/2001/XMLSchema#string

Elif Hindie

http://www.w3.org/2001/XMLSchema#string

Farid Sarandi

http://www.w3.org/2001/XMLSchema#string

Georges Baillet

http://www.w3.org/2001/XMLSchema#string

Jacques-Robert Vilcoq

http://www.w3.org/2001/XMLSchema#string

Jean-Emmanuel Filmont

http://www.w3.org/2001/XMLSchema#string

Jean-Louis Misset

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Moretti

http://www.w3.org/2001/XMLSchema#string

P304

695-704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJROBP.2008.02.056

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Marie-Elisabeth Toubert

Jacques-Robert Vilcoq

P577

2008-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18436392

http://www.w3.org/2001/XMLSchema#string